|
1
|
Burger M, Catto JW, Dalbagni G, Grossman
HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C,
Shariat S and Lotan Y: Epidemiology and risk factors of
urothelialbladder cancer. Eur Urol. 63:234–241. 2013. View Article : Google Scholar
|
|
2
|
Ferreccio C, Yuan Y, Calle J, Benítez H,
Parra RL, Acevedo J, Smith AH, Liaw J and Steinmaus C: Arsenic,
tobacco smoke and occupation: Associations of multiple agents with
lung and bladder cancer. Epidemiology. 24:898–905. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chavan S, Bray F, Lortet-Tieulent J,
Goodman M and Jemal A: International variations in bladder cancer
incidence and mortality. Eur Urol. 66:59–73. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Somlyo AP and Somlyo AV: Ca2+
sensitivity of smooth muscle and nonmuscle myosin II: Modulated by
G proteins, kinases and myosin phosphatase. Physiol Rev.
83:1325–1358. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hall A: Rho GTPases and the actin
cytoskeleton. Science. 279:509–514. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gómez del Pulgar T, Benitah SA, Valerón
PF, Espina C and Lacal JC: Rho GTPase expression in tumourigenesis:
Evidence for a significant link. Bioessays. 27:602–613. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Matsui T, Amano M, Yamamoto T, Chihara K,
Nakafuku M, Ito M, Nakano T, Okawa K, Iwamatsu A and Kaibuchi K:
Rho-associated kinase, a novel serine/threonine kinase, as a
putative target for small GTP binding protein Rho. EMBO J.
15:2208–2216. 1996.PubMed/NCBI
|
|
8
|
Duan WG, Yuan ST, Liao H, Yan M and Zhang
LY: Advances in the study of Rho kinase and its inhibitors. Yao Xue
Xue Bao. 42:1013–1022. 2007.In Chinese.
|
|
9
|
Itoh K, Yoshioka K, Akedo H, Uehata M,
Ishizaki T and Narumiya S: An essential part for Rho-associated
kinase in the transcellular invasion of tumor cells. Nat Med.
5:221–225. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Imamura F, Mukai M, Ayaki M and Akedo H:
Y-27632, an inhibitor of rhoassociated protein kinase, suppresses
tumor cell invasion via regulation of focal adhesion and focal
adhesion kinase. Jpn J Cancer Res. 91:811–816. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Volanis D, Zaravinos A, Kadiyska T,
Delakas D, Zoumpourlis V and Spandidos DA: Expression profile of
Rho kinases in urinary bladder cancer. J BUON. 16:511–521.
2011.PubMed/NCBI
|
|
12
|
Abe H, Kamai T, Hayashi K, Anzai N,
Shirataki H, Mizuno T, Yamaguchi Y, Masuda A, Yuki H, Betsunoh H,
et al: The Rho-kinase inhibitor HA-1077 suppresses
proliferation/migration and induces apoptosis of urothelial cancer
cells. BMC Cancer. 14:4122014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
von Dorp F, Sanders H, Boergermann C,
Lümmen G, Rübben H, Jakobs KH and Schmidt M: Inhibition of
Rho-kinase abrogates migration of human transitional cell carcinoma
cells: Results of an in vitro study. Urol Int. 86:220–227. 2011.
View Article : Google Scholar
|
|
14
|
Ueno K, Hirata H, Majid S, Yamamura S,
Shahryari V, Tabatabai ZL, Hinoda Y and Dahiya R: Tumor suppressor
microRNA-493 decreases cell motility and migration ability in human
bladder cancer cells by downregulating RhoC and FZD4. Mol Cancer
Ther. 11:244–253. 2012. View Article : Google Scholar
|
|
15
|
Kamai T, Tsujii T, Arai K, Takagi K, Asami
H, Ito Y and Oshima H: Significant association of Rho/ROCK pathway
with invasion and metastasis of bladder cancer. Clin Cancer Res.
9:2632–2641. 2003.PubMed/NCBI
|
|
16
|
Rösel D, Brábek J, Tolde O, Mierke CT,
Zitterbart DP, Raupach C, Bicanová K, Kollmannsberger P, Panková D,
Vesely P, et al: Upregulation of Rho/ROCK signaling in sarcoma
cells drives invasion and increased generation of protrusive
forces. Mol Cancer Res. 6:1410–1420. 2008. View Article : Google Scholar
|
|
17
|
Ying H, Biroc SL, Li WW, Alicke B, Xuan
JA, Pagila R, Ohashi Y, Okada T, Kamata Y and Dinter H: The Rho
kinase inhibitor fasudil inhibits tumor progression in human and
rat tumor models. Mol Cancer Ther. 5:2158–2164. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Horani A, Nath A, Wasserman MG, Huang T
and Brody SL: Rho-associated protein kinase inhibition enhances
airway epithelial Basal-cell proliferation and lentivirus
transduction. Am J Respir Cell Mol Biol. 49:341–347. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yu Z, Liu M, Fu P, Xie M, Wang W and Luo
X: ROCK inhibition with Y27632 promotes the proliferation and cell
cycle progression of cultured astrocyte from spinal cord. Neurochem
Int. 61:1114–1120. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mueller BK, Mack H and Teusch N: Rho
kinase, a promising drug target for neurological disorders. Nat Rev
Drug Discov. 4:387–398. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Huang HP, Wang CJ, Tsai JP, Wu SW, Hung
TW, Lian JD and Chang HR: Y27632 attenuates the aristolochic
acid-promoted invasion and migration of human urothelial cancer
TSGH cells in vitro and inhibits the growth of xenografts in vivo.
Nephrol Dial Transplant. 27:565–575. 2012. View Article : Google Scholar
|
|
22
|
Heneweer C, Kruse LH, Kindhäuser F,
Schmidt M, Jakobs KH, Denker H and Thie M: Adhesiveness of human
uterine epithelial RL95-2 cells to trophoblast: Rho protein
regulation. Mol Hum Reprod. 8:1014–1022. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fukata M, Nakagawa M and Kaibuchi K: Roles
of Rho-family GTPases in cell polarisation and directional
migration. Curr Opin Cell Biol. 15:590–597. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Song Y, Hoang BQ and Chang DD:
ROCK-II-induced membrane blebbing and chromatin condensation
require actin cytoskeleton. Exp Cell Res. 278:452–521. 2002.
View Article : Google Scholar
|
